Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 320 publications
Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.
Journal: NEJM evidence
Published: August 25, 2026
Stemness as the Engine of Checkpoint Durability.
Journal: The New England journal of medicine
Published: June 17, 2026
Defining the RNA Modification Landscape of Multiple Myeloma Reveals METTL3-Dependent m6A Regulation of NEAT1.
Journal: bioRxiv : the preprint server for biology
Published: April 17, 2026
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.
Journal: The New England journal of medicine
Published: April 03, 2026
Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data.
Journal: Transplantation and cellular therapy
Published: April 01, 2026
Streptavidin-drug conjugates streamline optimization of antibody-based hematopoietic stem cell transplant conditioning.
Journal: Blood immunology & cellular therapy
Published: January 23, 2026
Preventing graft re-JAK-tion: safer transplant conditioning enables murine islet allograft tolerance and diabetes reversal.
Journal: The Journal of clinical investigation
Published: January 02, 2026
Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma.
Journal: Nature communications
Published: November 18, 2025
The cancer genome and the birth of precision medicine.
Journal: Haematologica
Published: November 01, 2025
IL-7: a potential next-generation adjuvant for immune cell therapies.
Journal: Frontiers in immunology
Published: October 31, 2025
Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).
Journal: JCO precision oncology
Published: October 23, 2025
NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 06, 2025
Last Updated: 09/26/2026